Pacira Pharmaceuticals (PCRX) Posts Q2 Loss of 27c/Share
Get Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharmaceuticals (NASDAQ: PCRX) reported Q2 EPS of ($0.27), $0.16 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $8.77 million.
For earnings history and earnings-related data on Pacira Pharmaceuticals (PCRX) click here.
For earnings history and earnings-related data on Pacira Pharmaceuticals (PCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Aon plc (AON) Misses Q1 EPS by 23c
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!